TheraRadar

Briefs tagged "Biogen"

2 briefs

AbbVie Amgen Arvinas BMS Biogen CNS CRISPR Therapeutics Eisai Eli Lilly FDA IBD IGF-1R J&J Merck Novartis Pfizer Regeneron Roche Sandoz Sanofi TL1A Takeda Vertex autoimmune biosimilars bispecific cardiovascular competitive landscape drug development gene therapy genetics immunotherapy metabolic oncology ophthalmology patent cliff protein degradation rare disease regulatory
18 min read

Entyvio: The Only IBD Drug That Stays in the Gut

Eleven years after approval, Entyvio remains the only IBD drug that acts only in the gut — and two large pharma programs have failed trying to replicate it.

Tysabri (natalizumab) blocks α4 integrin broadly — and 541 patients developed fatal brain infections. Entyvio (vedolizumab) blocks only α4β7, which binds MAdCAM-1 on gut endothelium. One Greek letter difference. Over a million patient-years, no REMS, no MRI surveillance. Takeda's $6 billion franchise is built on that subtraction — and on a head-to-head trial where vedolizumab beat Humira directly in ulcerative colitis.

Read the full brief
autoimmuneIBDdrug developmentcompetitive landscapeTakeda
13 min read

Alzheimer's: 20 Years, 99% Failure, $42 Billion, Two Drugs

Two drugs finally broke through. They work only before most patients are ever diagnosed.

Alzheimer's drug development has a 99.6% failure rate - the highest of any disease. Between 2003 and 2021, zero new treatments were approved while $42.5 billion was spent on clinical trials. Then lecanemab and donanemab broke through. But 27% slowing of cognitive decline, brain swelling in up to 1 in 4 patients, and $26,000/year raises the question: is this enough?

Read the full brief
drug developmentCNScompetitive landscapeEisaiEli Lilly

Get the next Brief in your inbox — free

Every drug has multiple stories. Most never get told. One brief every week. No spam.

Archive lives at /briefs/. Unsubscribe anytime.